Ratti Francesca, Schadde Erik, Masetti Michele, Massani Marco, Zanello Matteo, Serenari Matteo, Cipriani Federica, Bonariol Luca, Bassi Nicolò, Aldrighetti Luca, Jovine Elio
Hepatopancreatobiliary Surgery Unit, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan, Italy,
Ann Surg Oncol. 2015;22(6):1933-42. doi: 10.1245/s10434-014-4291-4. Epub 2015 Jan 7.
Two-stage hepatectomy (TSH) is well established for the treatment of patients who have colorectal cancer liver metastases (CRLM) with a small liver remnant. The technique of associating liver partitioning and portal vein occlusion for staged hepatectomy (ALPPS) has been advocated as a novel tool to increase resectability. Using a case-match design, this study aimed to compare TSH and ALPPS for patients with CRLM.
All patients undergoing ALPPS for CRLM at three major hepatobiliary centers in Italy (ALPPS group) were compared in a case-match analysis with patients undergoing TSH (TSH group) at a single institution. The groups were matched with a 1:3 ratio using propensity scores based on covariates representing severity of metastatic disease. The main end points of the study were feasibility of complete resection and intra- and postoperative outcomes.
The two treatments did not differ significantly in feasibility. Two patients in the TSH group dropped out compared with no patients in the ALPPS group. A comparable volume gain in future liver remnant (FLR) was obtained in the ALPPS and TSH groups (47 vs. 41 %, nonsignificant difference) but during a shorter interval in ALPPS group. The overall and major complication rate was significantly higher after stage 2 in the ALPPS group (Clavien ≥ 3a: 41.7 vs. 17.6 % in TSH group; p = 0.025).
The feasibility of resection using ALPPS compared with TSH for CRLM was not significantly greater, but perioperative complications were increased. Therefore, ALPPS should be proposed to patients with caution and warnings. Currently, TSH remains the standard approach for performing R0 resection in patients with advanced CRLM and inadequate FLR.
对于肝残余量较小的结直肠癌肝转移(CRLM)患者,两阶段肝切除术(TSH)是一种成熟的治疗方法。联合肝脏分隔和门静脉结扎的分期肝切除术(ALPPS)技术被倡导为一种提高可切除性的新工具。本研究采用病例匹配设计,旨在比较TSH和ALPPS治疗CRLM患者的效果。
在意大利三个主要肝胆中心接受ALPPS治疗CRLM的所有患者(ALPPS组)与在单一机构接受TSH治疗的患者(TSH组)进行病例匹配分析。根据代表转移性疾病严重程度的协变量,使用倾向得分以1:3的比例对两组进行匹配。该研究的主要终点是完全切除的可行性以及术中和术后结果。
两种治疗方法在可行性方面无显著差异。TSH组有2例患者退出,而ALPPS组无患者退出。ALPPS组和TSH组未来肝残余(FLR)的体积增加相当(分别为47%和41%,无显著差异),但ALPPS组的时间间隔更短。ALPPS组在第二阶段后的总体和主要并发症发生率显著更高(Clavien≥3a:TSH组为17.6%,ALPPS组为41.7%;p = 0.025)。
与TSH相比,ALPPS用于CRLM切除的可行性并没有显著提高,但围手术期并发症增加。因此,应谨慎并告知患者相关风险后再推荐ALPPS。目前,TSH仍然是晚期CRLM且FLR不足患者进行R0切除的标准方法。